CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 44 enrolled
Drug / intervention
MBS-COV +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05677893
NCT05677893Phase 1Completed
CompareCT.gov

A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants

Oneness Biotech Co., Ltd.·interventional·Posted Jan 10, 2023·Updated Mar 30, 2025

In Brief

A Phase 1 clinical trial evaluating MBS-COV and Placebo for Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder). Completed, enrolled 44 participants across 1 site.

Detailed Summary

A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV in Healthy Participants

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDisease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedJan 10, 2023
Enrollment StartNov 7, 2022
Primary CompletionMar 30, 2023
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 3.5 years ago

Interventions

MBS-COVdrug

MBS-COV is a potent siRNA treatment for mild to moderate COVID-19.

Placeboother

Normal saline